<?xml version="1.0" encoding="UTF-8"?>
<billStatus>
  <bill>
    <sponsors>
      <item>
        <middleName />
        <party>D</party>
        <bioguideId>S001181</bioguideId>
        <lastName>Shaheen</lastName>
        <firstName>Jeanne</firstName>
        <state>NH</state>
        <identifiers>
          <lisID>1901</lisID>
          <bioguideId>S001181</bioguideId>
          <gpoId>8276</gpoId>
        </identifiers>
        <fullName>Sen. Shaheen, Jeanne [D-NH]</fullName>
        <byRequestType />
      </item>
    </sponsors>
    <version>1.0.0</version>
    <createDate>2017-05-16T00:26:38Z</createDate>
    <committeeReports />
    <latestAction>
      <text>Read twice and referred to the Committee on the Judiciary.</text>
      <links />
      <actionDate>2017-05-15</actionDate>
    </latestAction>
    <notes />
    <introducedDate>2017-05-15</introducedDate>
    <committees>
      <billCommittees>
        <item>
          <systemCode>ssju00</systemCode>
          <chamber>Senate</chamber>
          <type>Standing</type>
          <subcommittees />
          <name>Judiciary Committee</name>
          <activities>
            <item>
              <date>2017-05-15T20:29:35Z</date>
              <name>Referred to</name>
            </item>
          </activities>
        </item>
      </billCommittees>
    </committees>
    <relatedBills />
    <billNumber>1123</billNumber>
    <subjects>
      <billSubjects>
        <policyArea>
          <name>Crime and Law Enforcement</name>
        </policyArea>
        <legislativeSubjects>
          <item>
            <name>Afghanistan</name>
          </item>
          <item>
            <name>Asia</name>
          </item>
          <item>
            <name>Colombia</name>
          </item>
          <item>
            <name>Congressional oversight</name>
          </item>
          <item>
            <name>Criminal investigation, prosecution, interrogation</name>
          </item>
          <item>
            <name>Drug trafficking and controlled substances</name>
          </item>
          <item>
            <name>Drug, alcohol, tobacco use</name>
          </item>
          <item>
            <name>Environmental health</name>
          </item>
          <item>
            <name>Executive Office of the President</name>
          </item>
          <item>
            <name>Executive agency funding and structure</name>
          </item>
          <item>
            <name>Federal officials</name>
          </item>
          <item>
            <name>Government studies and investigations</name>
          </item>
          <item>
            <name>Hazardous wastes and toxic substances</name>
          </item>
          <item>
            <name>Health care coverage and access</name>
          </item>
          <item>
            <name>Health promotion and preventive care</name>
          </item>
          <item>
            <name>Internet and video services</name>
          </item>
          <item>
            <name>Latin America</name>
          </item>
          <item>
            <name>Peru</name>
          </item>
          <item>
            <name>Pest management</name>
          </item>
          <item>
            <name>Prescription drugs</name>
          </item>
          <item>
            <name>Specialized courts</name>
          </item>
          <item>
            <name>State and local government operations</name>
          </item>
        </legislativeSubjects>
      </billSubjects>
    </subjects>
    <amendments />
    <originChamber>Senate</originChamber>
    <cboCostEstimates />
    <policyArea>
      <name>Crime and Law Enforcement</name>
    </policyArea>
    <congress>115</congress>
    <actions>
      <item>
        <actionDate>2017-05-15</actionDate>
        <committee>
          <systemCode>ssju00</systemCode>
          <name>Judiciary Committee</name>
        </committee>
        <links />
        <sourceSystem>
          <code>0</code>
          <name>Senate</name>
        </sourceSystem>
        <text>Read twice and referred to the Committee on the Judiciary.</text>
        <type>IntroReferral</type>
      </item>
      <item>
        <actionDate>2017-05-15</actionDate>
        <actionCode>10000</actionCode>
        <text>Introduced in Senate</text>
        <committee />
        <links />
        <type>IntroReferral</type>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
      <actionTypeCounts>
        <referredToCommittee>1</referredToCommittee>
        <introducedInSenate>1</introducedInSenate>
      </actionTypeCounts>
      <actionByCounts>
        <senate>2</senate>
      </actionByCounts>
    </actions>
    <recordedVotes />
    <laws />
    <cosponsors>
      <item>
        <party>D</party>
        <state>NH</state>
        <bioguideId>H001076</bioguideId>
        <sponsorshipWithdrawnDate />
        <lastName>Hassan</lastName>
        <fullName>Sen. Hassan, Margaret Wood [D-NH]</fullName>
        <firstName>Margaret</firstName>
        <sponsorshipDate>2017-05-15</sponsorshipDate>
        <middleName>Wood</middleName>
        <isOriginalCosponsor>True</isOriginalCosponsor>
        <identifiers>
          <lisID>2302</lisID>
          <gpoId />
          <bioguideId>H001076</bioguideId>
        </identifiers>
      </item>
    </cosponsors>
    <titles>
      <item>
        <title>Office of National Drug Control Policy Reauthorization Act of 2017</title>
        <titleType>Short Titles as Introduced</titleType>
        <parentTitleType />
        <chamberCode />
        <chamberName />
      </item>
      <item>
        <title>A bill to reauthorize the Office of National Drug Control Policy, and for other purposes.</title>
        <titleType>Official Title as Introduced</titleType>
        <parentTitleType />
        <chamberCode />
        <chamberName />
      </item>
      <item>
        <title>Office of National Drug Control Policy Reauthorization Act of 2017</title>
        <titleType>Display Title</titleType>
        <parentTitleType />
        <chamberCode />
        <chamberName />
      </item>
      <item>
        <title>Office of National Drug Control Policy Reauthorization Act of 2017</title>
        <titleType>(Extracted from GPO) Short Titles as Introduced</titleType>
        <parentTitleType />
        <chamberCode />
        <chamberName />
      </item>
    </titles>
    <updateDate>2018-08-28T20:26:56Z</updateDate>
    <calendarNumbers />
    <billType>S</billType>
    <summaries>
      <billSummaries>
        <item>
          <updateDate>2017-05-15T04:00:00Z</updateDate>
          <actionDate>2017-05-15</actionDate>
          <lastSummaryUpdateDate>2017-12-20T21:43:24Z</lastSummaryUpdateDate>
          <text><![CDATA[<p><b>Office of National Drug Control Policy Reauthorization Act of 2017</b></p> <p>This bill reauthorizes the Office of National Drug Control Policy through FY2023. It amends the definition of &quot;demand reduction&quot; in a National Drug Control Program to include screenings, interventions, promoting availability of and access to health care services, and support for long-term recovery from substance abuse disorders. It defines &quot;illicit drug use,&quot; &quot;illegal drug use,&quot; and like terms to include the illegal use of prescription drugs.</p> <p>The Director of the National Drug Control Policy (Director) shall be directly responsible for demand reduction activities, supply reduction activities, and for state, local, and tribal affairs.</p> <p>The Director shall require each National Drug Control Program agency to submit to the Director on an annual basis an evaluation of progress by the agency regarding implementation of drug recovery programs. The Director shall also ensure that drug recovery research is effectively disseminated by the National Drug Control Program agencies to state and local governments and nongovernmental agencies involved in demand reduction.</p> <p>The President shall submit to Congress a National Drug Control Strategy, which shall set forth a comprehensive plan for the year to reduce illicit drug use and the consequences of such use by promoting prevention, early intervention, treatment, and recovery support for individuals with substance abuse disorders.</p> <p>The Director shall submit to Congress a report evaluating high intensity drug trafficking areas (HIDTAs) as part of the National Drug Control Strategy, assessing drug enforcement task forces in HIDTAs, and assessing law enforcement intelligence sharing in HIDTAs.</p>]]></text>
          <actionDesc>Introduced in Senate</actionDesc>
          <versionCode>00</versionCode>
          <name>Introduced in Senate</name>
        </item>
      </billSummaries>
    </summaries>
    <title>Office of National Drug Control Policy Reauthorization Act of 2017</title>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>

